Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.

ABSTRACT:

Background

Pancreatic cancer represents the third leading cause of US cancer deaths, with median survival <1 year. The goal of this study was to describe systemic treatments, healthcare utilization and costs, and overall survival among patients with unresectable/metastatic disease.

Methods

This study used healthcare claims for commercial and Medicare Advantage enrollees diagnosed with pancreatic adenocarcinoma (at index date) during January 01 2010 to 31 May 2017. Included patients were aged ≥18 years, with continuous 6-month preindex enrollment. Patients were excluded by resectable disease, another primary cancer, or pregnancy. Cohorts were based on first-line (LOT1) chemotherapy regimen.

Results

Overall, 12 978 patients (mean age 70 years, 51% male) were included, a

SUBMITTER: Doleh Y 

PROVIDER: S-EPMC7221424 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature